Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1-2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Surgically Operable or Advanced Stage Ovarian, Fallopian Tube or Peritoneal Cancer

NCT01416038 is registered in ClinicalTrials.gov with ImmunoVaccine Technologies, Inc. (IMV Inc.) as lead sponsor.

NCT NCT01416038
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01416038 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1-2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Surgically Operable or Advanced Stage Ovarian, Fallopian Tube or Peritoneal Cancer
Lead sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2011
Completion date
May 31, 2013
Enrollment
19 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, ovarian cancer, peritoneal cancer